Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial-Reference-Cited by-同舟云学术

Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial

Published:2022-05 Issue:5 Volume:22 Page:718-730
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Kumar Deepali,Ison Michael G,Mira Jean-Paul,Welte Tobias,Hwan Ha Jick,Hui David S,Zhong Nanshan,Saito Takefumi,Katugampola Laurie,Collinson Neil,Williams Sarah,Wildum Steffen,Ackrill Andrew,Clinch Barry,Lee Nelson

Funder

F. Hoffmann-La Roche

Biomedical Advanced Research and Development Authority

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference27 articles.

1. Diagnosis, management and outcomes of adults hospitalized with influenza;Lee;Antivir Ther,2012

2. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data;Muthuri;Lancet Respir Med,2014

3. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09;Louie;Clin Infect Dis,2012